Abstract:Background. A large number of cancer-related deaths in the world can be attributed to liver hepatocellular carcinoma (LIHC). The purpose of this study is to explore protein tyrosine phosphatase type IV A member 3 (PTP4A3/PRL-3) as a new and reliable biomarker to predict the prognosis of LIHC and determine the potential therapeutic targets or drugs that can be used for treating LIHC. Methods. We included three LIHC datasets with clinical information and expression profiles from public databases. The expression level of PTP4A3 was analyzed, and based on the results, the samples were divided into high- and low-expression groups. The Kaplan–Meier survival analysis method was used to determine the relationship between PTP4A3 and prognosis. The enrichment differences among the functional pathways associated with the high- and low-expression groups were determined using the gene set enrichment analysis (GSEA) method. Five methods were used to determine the differences among the tumor microenvironment in the low- and high-expression groups. The sensitivity of the low- and high-expression groups toward different drug treatment methods was predicted by analyzing the Tumor Immune Dysfunction and Exclusion (TIDE) scores and determining the biochemical half-maximal inhibitory concentration (IC50). Results. The expression levels of the LIHC and adjacent samples were analyzed, and it was observed that the expression level of PTP4A3 in tumor tissue was significantly higher than the expression level of the same gene in the adjacent samples. It was also inferred that it might be a cancer-promoting gene. It was concluded that high-expression results in a significantly poor prognosis. The high-expression group was significantly enriched in the tumor-related pathways, such as the PI3K-AKT signaling pathway. In addition, the results obtained by conducting immune infiltration analysis revealed a significant positive correlation between some immune scores and the gene PTP4A3. The drug KIN001−135 and gene PTP4A3 were also found to correlate positively with each other. CP466722, Pyrimethamine, AKT inhibitor VIII, Embelin, Cisplatin, QS11, Bexarotene, and Midostaurin negatively correlated with PTP4A3 associated with the three datasets. Moreover, the drugs Cisplatin, QS11, Midostaurin, and CP466722 were more sensitive toward the high-expression group than the low PTP4A3 expression group. Significant differences were observed in these cases. Conclusion. PTP4A3/PRL-3 is potentially associated with the progression, metastasis, and invasion of LIHC. The prognosis of LIHC patients is negatively impacted by the high-expression levels of the gene. The results indicate that PTP4A3/PRL-3 is an important prognostic factor for LIHC and is a new potential prognostic detection target. The discovery of the 8 drugs that were negatively associated with PTP4A3 provided a new direction that can be developed in the future for the treatment of LIHC.

PRL-3 Facilitates Hepatocellular Carcinoma Progression by Co-Amplifying with and Activating FAK

Phosphatase Regenerating Liver 3 Participates in Integrinβ1/FAK-Src/MAPK Signaling Pathway and Contributes to the Regulation of Malignant Behaviors in Hepatocellular Carcinoma Cells

Protein Tyrosine Phosphatase PRL-3: A Key Player in Cancer Signaling

Metastasis-associated PRL-3 Induces EGFR Activation and Addiction in Cancer Cells

PTPRε Acts as a Metastatic Promoter in Hepatocellular Carcinoma by Facilitating Recruitment of SMAD3 to TGF‐β Receptor 1

PRL-3 Activates Mtorc1 in Cancer Progression

Ptpr Epsilon Acts As A Metastatic Promoter In Hepatocellular Carcinoma By Facilitating Recruitment Of Smad3 To Tgf-Beta Receptor 1

Evaluation of Prl-3 Expression, and Its Correlation with Angiogenesis and Invasion in Hepatocellular Carcinoma

Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells.

Characterizing PTP4A3/PRL-3 as the Potential Prognostic Marker Gene for Liver Hepatocellular Carcinoma

PRL-3 Activates NF-κB Signaling Pathway by Interacting with RAP1.

Oncogenic Roles of Prl-3 in Flt3-Itd Induced Acute Myeloid Leukaemia

Phosphatase of Regenerating Liver-3 (PRL-3) is Associated with Metastasis and Poor Prognosis in Gastric Carcinoma

PRL-3 promotes ubiquitination and degradation of AURKA and colorectal cancer progression via dephosphorylation of FZR1.

PRL-3 Promotes the Malignant Progression of Melanoma Via Triggering Dephosphorylation and Cytoplasmic Localization of NHERF1

PRL-3 promotes cell adhesion by interacting with JAM2 in colon cancer.

PRL-3 promotes gastric cancer peritoneal metastasis via the PI3K/AKT signaling pathway in vitro and in vivo .

PRL-3 promotes the peritoneal metastasis of gastric cancer through the PI3K/Akt signaling pathway by regulating PTEN.

PRL-3 Promotes Gastric Cancer Migration and Invasion Through a NF-κB-HIF-1α-miR-210 Axis.

PTPN3 suppresses the proliferation and correlates with favorable prognosis of perihilar cholangiocarcinoma by inhibiting AKT phosphorylation

PRL1 and PRL3 promote macropinocytosis via its lipid phosphatase activity